WeTrials
Recruiting

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants With Hematologic Malignancies

What is this study?

This study is testing an experimental medication called nemtabrutinib to see how well it works and if it is safe for people with certain types of blood and lymph system cancers. Researchers hope this targeted treatment will help fight these specific conditions while keeping side effects manageable.

Who can participate?

You may be able to join if you have been diagnosed with one of the specified blood or lymph cancers, are able to swallow pills, and are well enough to go about your daily activities. There are also specific health requirements regarding past treatments and infections like hepatitis to keep you safe.

What will happen?

Participants will take the study medication in pill or capsule form and have regular check-ups with the medical team to monitor your health and response to the treatment. Your doctors will carefully track your progress and check for any side effects throughout the study.

Where and when?

This study is currently recruiting participants at multiple locations, including Springdale, Arkansas, and La Jolla and Torrance, California. Speak with your doctor to see if one of these locations is convenient for you.

Key Points
  • 1Testing a new targeted pill called nemtabrutinib for blood and lymph cancers
  • 2Currently recruiting patients who meet specific health and daily activity criteria
  • 3Takes place at multiple medical centers in Arkansas and California

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins LymphomaChronic Lymphocytic Leukaemia

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.